FBXO46

Across TCGA pan-cancer cohorts, FBXO46 RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of FBXO46’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FBXO46 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FBXO46 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

KIRC, BLCA, and LIHC are the cancer types where FBXO46 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FBXO46 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.364	<.001	11	view →
BLCA	All	All	+0.634	<.001	9	view →
LIHC	Female	II,III,IV	+1.255	<.001	8	view →
LUSC	All	II,III,IV	+0.848	<.001	7	view →
HNSC	Male	All	+0.706	<.001	7	view →
BRCA	All	III,IV	+0.866	<.001	6	view →
STAD	All	II,III,IV	+0.723	<.001	6	view →
UCEC	All	All	+0.551	<.001	6	view →
COAD	All	All	+0.315	<.001	6	view →
LUAD	All	All	+0.284	.003	6	view →
CHOL	Male	All	+2.146	<.001	5	view →
KICH	All	All	−0.626	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 17 lineages.

FBXO46–KIRC

Open the KIRC breakdown →